Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05999292
Other study ID # R8760-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 11, 2023
Est. completion date April 2024

Study information

Verified date October 2023
Source Radionetics Oncology
Contact Istvan Molnar, MD
Phone 201-912-6062
Email imolnar@radionetics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Adrenocortical Carcinoma Subjects Inclusion Criteria: 1. Pathologically confirmed ACC. 2. Newly diagnosed or recurrent/relapsed ACC with at least 1 measurable target lesion per RECIST v1.1 criteria. 3. Male or non-pregnant, non-lactating female subjects age =18 years. 4. Female subjects of childbearing potential and male subjects (if sexually active) must agree to use adequate method(s) of effective contraception during their participation in the study. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status =2. 6. Adequate hepatic function as defined below: 1. Serum alanine aminotransaminase (ALT)/ aspartate aminotransaminase (AST) =3 × upper limit of normal (ULN) or =5 × ULN if liver metastases are present or received prior mitotane therapy, and 2. Serum bilirubin - total =1.5 × ULN (unless due to Gilbert's syndrome or hemolysis in which case total =3.0 × ULN). 7. Adequate renal function as measured by creatinine clearance calculated by the Cockcroft-Gault formula (=60 mL/minute). 8. Able to understand and willing to sign a written informed consent form. Exclusion Criteria: 1. Administered a radionuclide within a period of time corresponding to less than 10 physical half-lives of the radionuclide prior to study Day 1. 2. Radiotherapy =14 days prior to study Day 1. 3. Major surgery =21 days prior to study Day 1 or has not recovered from adverse effects of such procedure. 4. Severe or unstable medical condition, such as congestive heart failure (New York Heart Association [NYHA] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, as well as an uncontrolled cardiac arrhythmia requiring medication (=Grade 2, according to NCI-CTCAE Version 5.0), myocardial infarction within 6 months prior to starting study drug, or any other significant or unstable concurrent cardiac illness. Note: Stable chronic atrial fibrillation is allowed. 5. Congenital long QT syndrome or corrected QT interval by Fridericia (QTcF) interval >450 msec (males) or >470 msec (females). 6. History of cerebrovascular accident within 6 months or that resulted in ongoing neurologic instability. 7. History of other previous or concurrent cancer that would interfere with the determination of safety. 8. Major active infection requiring antibiotics. 9. Known active human immunodeficiency virus infection or active infection with Hepatitis B or C. 10. Acute illness within 14 days prior to study Day 1unless mild in severity, as assessed by the Investigator. 11. Any other condition that in the opinion of the Investigator would place the subject at an unacceptable risk or cause the subject to be unlikely to fully participate or comply with study procedures. Healthy Volunteers Inclusion Criteria: 1. Healthy male or non-pregnant, non-lactating female subjects aged between 18 and 59 years (inclusive). 2. Female subjects of childbearing potential and male subjects (if sexually active) must agree to use adequate method(s) of effective contraception during their participation in the study. 3. Body mass index between 18.0 and 32.0 kg/m2 (inclusive). 4. Adequate renal function as measured by creatinine clearance calculated at =60 mL/minute by the Cockcroft-Gault formula. 5. Able to understand and willing to sign a written informed consent form. Exclusion Criteria: 1. Prior unilateral or bilateral adrenalectomy. 2. Mental or legal incapacitation. 3. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). 4. Subjects diagnosed with adrenal disease, including Cushing's syndrome, adrenal insufficiency, or congenital adrenal hyperplasia. 5. Glucocorticoid steroid use (including topical) within 4 weeks prior to study Day 1 (inhaled steroids are allowed). 6. Active or recent (within 30 days of screening) infection or history of recurrent chronic infections with underlying condition that may predispose one to infections. 7. Resting pulse rate =100 or <40 beats per minute at screening. If abnormal, a repeat measurement will be conducted to confirm. 8. Systolic blood pressure >160 or <90 mmHg or diastolic blood pressure >90 or <50 mmHg, unless judged by the Investigator to have no clinical significance. 9. Participation in a clinical study involving administration of an investigational drug in the past 30 days or 5 half-lives (whichever is longer) prior to study Day 1. 10. Administered a radionuclide within a period of time corresponding to less than 10 physical half-lives of the radionuclide prior to study Day 1. 11. Donation of blood or significant blood loss within 3 months prior to screening, donation of plasma within 2 weeks prior to screening, or donation of platelets within 6 weeks prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
68Ga-R8760 injection at pre-defined dose levels
PET/CT imaging at predefined timepoints
68Ga-R8760 injection
PET/CT imaging at a single timepoint

Locations

Country Name City State
United States University of Michigan Nuclear Medicine Ann Arbor Michigan
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Radionetics Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events characterized overall and by type, frequency, seriousness, relationship to study drug, timing and severity graded according to the NCI-CTCAE v5.0; absolute values and changes in clinical laboratory parameters 7 days
Primary Absorbed dose coefficients (mGy/MBq) in target organs and the effective dose coefficient (mSv/MBq) 1 day
Secondary Number and location of tumors identified by 68Ga-R8760 PET/CT and by anatomic images 1 day
Secondary Maximum standard uptake value (SUVmax) of each tumor and of source organ 1 day
Secondary Ratio of the tumor SUV over reference region SUV 1 day
Secondary Area under the plasma concentration versus time curse (AUC) 1 day
Secondary Maximum plasma concentration (Cmax) 1 day
Secondary Half-life (T1/2) of 68Ga-R8760 1 day
See also
  Status Clinical Trial Phase
Completed NCT04373265 - Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Phase 1
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT06066333 - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Phase 2
Recruiting NCT03127774 - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Completed NCT05361083 - First-in-human Evaluation of [18F]CETO Early Phase 1
Recruiting NCT05660889 - Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
Completed NCT00003038 - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Enrolling by invitation NCT05036434 - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Phase 2
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Withdrawn NCT00469469 - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Phase 2
Completed NCT00002608 - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Phase 2
Not yet recruiting NCT05839886 - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting NCT05634577 - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Phase 2
Completed NCT00454103 - Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Phase 1/Phase 2